Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

Tofacitinib may effectively treat folliculitis decalvans.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Tofacitinib treatment for hair loss may worsen acne.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.

Tofacitinib effectively improved severe skin symptoms in a patient with Hypohidrotic Ectodermal Dysplasia.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

A man's hair regrew from alopecia areata after using tofacitinib and experiencing contact dermatitis from a wig device.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

Tofacitinib may help treat hair loss in children with alopecia areata.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.

Topical tofacitinib shows promise as a future treatment for alopecia areata.